Genentech's Vamikibart Shows Sustained Efficacy in UME Phase III…

Event summary

Genentech presented one-year data from Phase III MEERKAT and SANDCAT trials showing sustained vision improvements and reduced macular thickness in UME patients treated with vamikibart.
The FDA accepted Genentech’s Biologics License Application (BLA) for vamikibart, with a decision expected by July 2027.
Vamikibart demonstrated a favorable safety profile with low treatment-related ocular adverse events and intraocular inflammation.
Regulatory submissions for vamikibart have been accepted in the European Union, China, and Japan.

The big picture

Genentech's vamikibart represents a significant advancement in the treatment of uveitic macular edema (UME), a condition currently managed with off-label therapies or steroids that carry long-term risks. The sustained efficacy and favorable safety profile demonstrated in Phase III trials position vamikibart as a potential game-changer in ophthalmology, addressing a critical unmet need in the treatment of this sight-threatening condition. The acceptance of the BLA by the FDA and other regulatory bodies underscores the global interest in this innovative therapy.

What we're watching

Regulatory Approval: Whether the FDA will approve vamikibart by July 2027, potentially making it the first non-steroid targeted treatment for UME.
Market Adoption: The pace at which vamikibart could establish a new standard of care for UME, given its sustained efficacy and favorable safety profile.
Competitive Landscape: How Genentech's vamikibart will position against existing off-label therapies and ocular steroids in the UME treatment market.